When combined with chemotherapy, anti-VEGF antibodies can alleviate hypoxia and acidosis, which contribute to chemotherapy resistance and improve outcomes of advanced NSCLC patients [11]. Here, VEGFA is linked to non-small cell lung carcinoma.